Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.

Profound disruption of immune function is an established risk factor for non-Hodgkin lymphoma. We report here a large-scale evaluation of common genetic variants in immune genes and their role in lymphoma. We genotyped 57 single nucleotide polymorphisms (SNP) from 36 candidate immune genes in 1,172 non-Hodgkin lymphoma cases and 982 population-based controls from a US multicenter study. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the association between individual SNP and haplotypes with non-Hodgkin lymphoma overall and five well-defined subtypes. A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007). A functional nonsynonymous SNP in the innate immune gene Fc gamma receptor 2A (FCGR2A; rs1801274) was also associated with non-Hodgkin lymphoma; AG and AA genotypes were associated with a 1.26-fold (95% CI, 1.01-1.56) and 1.41-fold (95% CI, 1.10-1.81) increased risk, respectively (P(trend) = 0.006). Among non-Hodgkin lymphoma subtypes, the association with FCGR2A was pronounced for follicular and small lymphocytic lymphomas. In conclusion, common variants in genes influencing proinflammatory and innate immune responses were associated with non-Hodgkin lymphoma risk overall and their effects could vary by subtype. Our results require replication but potentially provide important clues for investigating common genetic variants as susceptibility factors and in disease outcomes, treatment responses, and immunotherapy targets.

[1]  G. Salles,et al.  Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. , 1998, Blood.

[2]  Y. Choi,et al.  Follicular Dendritic Cells Produce IL-15 That Enhances Germinal Center B Cell Proliferation in Membrane-Bound Form1 , 2004, The Journal of Immunology.

[3]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[4]  J. Marx.  Cancer research. Inflammation and cancer: the link grows stronger. , 2004, Science.

[5]  F. Arnett,et al.  Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. , 1996, The Journal of clinical investigation.

[6]  N. Hamasaki,et al.  Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. , 1998, Nature genetics.

[7]  L. Keen.  The extent and analysis of cytokine and cytokine receptor gene polymorphism. , 2002, Transplant immunology.

[8]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[9]  J. Ioannidis,et al.  The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases , 2004 .

[10]  I. Magrath.  Molecular characteristics of diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[11]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[12]  S. Ahmed,et al.  Polymorphism in the tumor necrosis factor‐α promotor region and in the heat shock protein 70 genes associated with malignant tumors , 1997, Cancer.

[13]  D. Fitzpatrick,et al.  Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. , 2003, Clinical immunology.

[14]  J. Satsangi,et al.  Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies , 2000, Genes and Immunity.

[15]  M. Carrington,et al.  Cutting Edge: Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and Killer Ig-Like Receptor Combinations in Psoriatic Arthritis1 , 2004, The Journal of Immunology.

[16]  A. Hajeer,et al.  TNF-alpha gene polymorphism: clinical and biological implications. , 2000, Microscopy research and technique.

[17]  Keith Hoots,et al.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.

[18]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Chanock,et al.  Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  M. Max,et al.  Haplotype structure of inflammatory cytokines genes (IL1B, IL6 and TNF/LTA) in US Caucasians and African Americans , 2004, Genes and Immunity.

[21]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[22]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[23]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[24]  L. Staudt,et al.  Clinical translation of gene expression profiling in lymphomas and leukemias. , 2002, Seminars in oncology.

[25]  October 1 , 1966 .

[26]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[27]  J. Ioannidis,et al.  Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. , 2002, Arthritis and rheumatism.

[28]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[29]  S. Proctor,et al.  Tumour Necrosis Factor Gene Polymorphisms in Lymphoproliferative Disease , 2000, Leukemia & lymphoma.

[30]  J. Cerhan,et al.  Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.

[32]  J. Friedland.  Chemokines and human infection. , 1995, Clinical science.

[33]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[34]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[35]  Jinbo Chen,et al.  Genetic Variation and Willingness to Participate in Epidemiologic Research: Data from Three Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[36]  R. Westendorp,et al.  Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.

[37]  H. Adami,et al.  Family history of hematopoietic malignancy and risk of lymphoma. , 2005, Journal of the National Cancer Institute.

[38]  K. Buetow,et al.  Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  Jean Marx,et al.  Inflammation and Cancer: The Link Grows Stronger , 2004, Science.

[40]  J. Satsangi,et al.  Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. , 2000, Genes and immunity.

[41]  Brian Staats,et al.  SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes , 2004, Nucleic Acids Res..

[42]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[43]  Stephen J O'Brien,et al.  Human genes that limit AIDS , 2004, Nature Genetics.

[44]  T. Mak,et al.  The Role of Interleukin 13 in Classical Hodgkin Lymphoma , 2002, Leukemia & lymphoma.

[45]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[46]  K. Huppi,et al.  Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. , 1999, Blood.

[47]  L. Staudt,et al.  Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation , 2002, Nature Reviews Immunology.

[48]  U. Spengler,et al.  Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF- beta production , 1991, The Journal of experimental medicine.

[49]  P. Donnelly,et al.  The effects of human population structure on large genetic association studies , 2004, Nature Genetics.

[50]  T. Lister,et al.  Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma , 1999, British journal of haematology.

[51]  F. Collins,et al.  Welcome to the genomic era. , 2003, The New England journal of medicine.

[52]  J. Casanova,et al.  Inherited disorders of cytokines , 2004, Current opinion in pediatrics.

[53]  F. Arnett,et al.  Rapid Publication Fc g RIIA Alleles Are Heritable Risk Factors for Lupus Nephritis in African Americans , 1996 .

[54]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[55]  Erik Björck,et al.  with follicular lymphoma High expression of cyclin B 1 predicts a favorable outcome in patients , 2004 .

[56]  R. Germain.  An innately interesting decade of research in immunology , 2004, Nature Medicine.

[57]  T. Ottenhoff,et al.  Is there a future for TNF promoter polymorphisms? , 2004, Genes and Immunity.

[58]  B. Moser,et al.  Chemokines: role in inflammation and immune surveillance , 2004, Annals of the rheumatic diseases.

[59]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[60]  G. Salles,et al.  Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. , 2002, Blood.

[61]  M. Monne,et al.  Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) gene polymorphism and susceptibility to non‐Hodgkin's lymphoma , 2004, American journal of hematology.